



April 24, 2018

Carlo de Notaristefani
Executive Vice President, Teva Global Operations
400 Interpace Pkwy, Building A
Parsippany, NJ 07054

Dear Mr. de Notaristefani:

The U.S. Food and Drug Administration is pleased to announce that Teva is selected to receive a Drug Shortage Assistance Award for its role in preventing or alleviating a drug shortage.


Teva is being recognized for its efforts related to the prevention of a shortage of Trisenox (arsenic trioxide) injection, including building an inventory of product, allowing continued availability of product for patients.

FDA established this award program to recognize companies for making a substantial contribution to preventing or alleviating a drug shortage. FDA hopes this award serves as an incentive for other companies to assist in addressing drug shortages, as Teva has.

The intent of the award program is to bring attention to manufacturers or companies that assist in addressing a drug shortage and prioritize quality manufacturing, a key component of the Strategic Plan for Preventing and Mitigating Drug Shortages. More information on the strategic plan can be found on FDA's drug shortages web page (<http://www.fda.gov/drugs/drugsafety/drugshortages/default.htm>).

FDA thanks Teva for working to prevent the shortage of Trisenox. The enclosed press release/web statement template is provided to assist you in publicizing your award from FDA.

Sincerely,


Douglas C. Throckmorton, M.D.
Deputy Center Director for Regulatory Programs,
FDA, Center for Drug Evaluation and Research

Enclosure(s):
Certificate
Optional Press Release/Web Statement Template